The USA's Federal Trade Commission has sent letters to 11 companies that promote various omega-3 fatty acid supplements, telling them they should review their product packaging and labeling to make sure they do not violate federal law by making baseless claims about how the supplements benefit children's brain and vision function and development.
The FTC sent letters to the companies last month, cautioning that their product packaging and advertising might be in violation of the FTC Act unless they have scientific evidence to support claims that their products boost, improve, enhance, or support brain and vision function and development in children. Also included are claims relating to intelligence, cognitive function, learning ability, focus, mood, memory, attention, concentration, visual acuity and eye health.
In the warning letters, the FTC gave the companies two weeks to respond and explain the steps they have taken, or intend to take, to ensure they are complying with the law. The agency warned that it may take law enforcement action if they make health-related claims for products without scientific proof.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze